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Gout is a disorder of uric acid metabolism
and represents a heterogeneous group of diseases that
include (1).
• An elevated serum urate concentration
• Recurrent attacks of acute arthritis in which Monosodium
Urate (MSU) crystals are seen in synovial fluid
• Aggregates of MSU crystals (tophi) are deposited
in & around joints leading to deformity & crippling
• Renal disease involving glomerular, tubular,
interstitial tissue & blood vessels
• Uric acid nephrolithiasis
Hyperuricemia (1)
• An elevated level of urate in the blood > 7mg/dl in
males and >6.5mg/dl in females.
Gout is an important cause of arthritis and the
prevalence is on the increase. The incidence of gout
varies in population with an overall prevalence of
less than 1 to 15.3% (2). The Bhigwan COPCORD
survey demonstrated low prevalence of Gout (0.12%)
in rural India (3). In another Indian study gout
prevalence was 2% (4). In study from Jammu only
two case of gout were reported (5)
Gout once called the “disease of kings,” is also seen
in women, especially after menopause. The male female
ratio changes as estrogen status changes (Table-1)
Table-1 Male : Female Ratio
Normally M:F ratio is  - 7:1 to 9:1(6)
Women before menopause- F < M
In ages younger than 65- M:F- 4:1 ratio
In the older age groups > 65- M:F-3:1 ratio (7)
After 80 years of age-F > M (6, 8)
It is largely because estrogenic hormones have a mild
uricosuric effect; therefore, gout is unusual in
premenopausal women. There is higher renal clearance
of urate in women possibly due to their higher plasma
estrogen levels and significantly lower tubular urate
postsecretory reabsorption (9). The declining use of HRT
may further increase the frequency of gout in women at
an earlier age (10)
Differences do exist in Pathogenesis of Gout
(Men Vs Women) (9, 11, 12)
• Renal under excretion of uric acid appears to
be more severe in female than in male patients
with gout.
• These differences are significant and independent
of the effects of age, renal insufficiency, alcoholism,
or previous diuretic intake.
Table-2 Triggering Factors-Acute Attack remain
same for both men and women (1)
Alcohol ingestion
Dietary excess of purine
Hemorrhage
Acute medical illness
Infections
Exercise
Trauma
Surgery
Drugs : cyclosporine, furosemide, ethambutol, aspirin
(Low dose), pyrazinamide, thiazides, nicotinic acids etc
Differences also exist in Clinical Features
(Men Vs Women) (9,11-13).
• In women, polyarticular/tophaceous disease is often
the first manifestation of gout.
• A preceding recurrent mono-arthritis is found in
joints other than the big toe.
• The duration of disease before tophi is shorterJK SCIENCE
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• The prevalence of tophi is higher and its localization
is different in female than in male patients
• Tophi are usually indolent and show little
surrounding inflammation.
• Gout in women has higher frequency of upper limb
joint involvement in comparison to men
• The articular features of gout are usually similar
Definitive diagnosis is best established by (1).
• Aspiration of joint and identification of urate crystal
• The triad of acute monoarticular arthritis,
hyperuricemia and dramatic response to colchicines
• Presence of 6 of the 12 clinical, laboratory and
radiographic criteria  by ACR15
Differences also exist in co-morbid conditions (11-13)
(Men Vs Women)
Associated co-morbidities such as hypertension,
ischemic heart diseases or chronic renal failure is frequent
in women. This may be due to the fact that disturbance
of the metabolism due to estrogen deficiency occurs
during menopause leading to decrease in HDL and
increase in LDL, promoting arteriosclerosis accompanied
by an increase risk of myocardial infarction, angina,
Hypertension and stroke. Renal underexcretion of uric
acid appears to be more severe in female than in male
patients with gout, which increases the possiblility of
co-morbid renal abnormalities in women with gout.
Treatment of Gout have the same goals as  for any
patient (14-16)
• Treat acute arthritic attack promptly
• Prevent recurrence of acute gouty arthritis
• Lower urate levels
• Prevent or reverse complications of the disease
resulting from deposition of MSU crystal in joint,
kidney, or other sites
• Prevent or reverse co-morbid conditions like obesity,
Hypertension and triglyceridemia and renal complications
Pharmacologic management remains the mainstay of
treatment. Acute attacks may be terminated with the use
of nonsteroidal anti-inflammatory agents, colchicine or
intra-articular injections of corticosteroids. Probenecid,
sulfinpyrazone and allopurinol can be used to prevent
recurrent attacks. New drugs such as rasburicase and
febuxostat promise equal efficacy with a possibility of
fewer adverse effects. Obesity, alcohol intake and certain
foods and medications can contribute to hyperuricemia
thus, they should be avoided.
 The effect of exogenously administered oestrogens,
produce a fall in plasma uric acid concentration through a
uricosuric effect. There is no conclusive evidence available
for the use of estrogen replacement for such cases; however
it remains the potential area of research.
In conclusion an early identification, comprehensive
care and treatment of comorbid conditions is important
in management of gout in women during and after
menopause to reduce the menace of dual problem.
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